Current Immune Checkpoint Inhibitor Genetic Biomarker Exploration in Gastrointestinal Tumors

SIMPLE SUMMARY: Immune checkpoint inhibitors (ICIs) are now incorporated into the management of GI tumors. The heterogenous nature of these tumors, however, reveals a lack of ICI consistency in effectiveness. Certain biomarkers have emerged as being potentially predictive for ICI effectiveness. Our...

Descripción completa

Detalles Bibliográficos
Autores principales: Rogers, Jane E., Yamashita, Kohei, Sewastjanow Silva, Matheus, Ajani, Jaffer A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9563283/
https://www.ncbi.nlm.nih.gov/pubmed/36230726
http://dx.doi.org/10.3390/cancers14194804

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9563283/
https://www.ncbi.nlm.nih.gov/pubmed/36230726
http://dx.doi.org/10.3390/cancers14194804

Ejemplares similares